Fig. 1

The efficiency of SERCA2a overexpression. E2 increased SERCA2a expression in NRCMs. a MOI of Ad-SERCA2a and Ad-EGFP in NRCMs. b The effects of different concentrations of E2 solution on SERCA2a expression in vitro (n = 3; ***P < 0.001 vs. con; ^##P < 0.01, ^### P < 0.001 vs. 10 nM). c The mRNA and protein expression of SERCA2a after Ad-SERCA2a or Ad-EGFP infection (n = 5; ***P < 0.001 vs. Sham; ^###P < 0.001 vs. Ad-EGFP). d SERCA2a protein expression in vivo (n = 3; *P < 0.05, ***P < 0.001 vs. sham; ^#P < 0.05, ^##P < 0.01, ^###P < 0.001 vs. OVX; ^$P < 0.05, ^$$$P < 0.001 vs. OVX + E2; ^%%P < 0.01, ^%%%P < 0.001 vs. I/R; ^&&P < 0.01, ^&&&P < 0.001 vs. OVX + I/R; ^@@@P < 0.001 vs. OVX + E2 + I/R; ^{^^^}P < 0.001 vs. Ad-EGFP + I/R). e SERCA2a protein expression in vitro (n = 3; ^*P < 0.05, **P < 0.01, ***P < 0.001 vs. con; ^#P < 0.05, ^##P < 0.01, vs. H/R; ^$P < 0.05, ^$$P < 0.01 vs. E2 + H/R; ^%%P < 0.01 vs. Ad-EGFP + H/R; ^&&P < 0.01, ^&&&P < 0.001 vs. Ad-SERCA2a + H/R; ^@@P < 0.01 vs. si-NC + H/R; ^{^^^}P < 0.001 vs. si-SERCA2a + H/R; ^aaaP < 0.001 vs. Ad-SERCA2a + E2 + H/R)